67
Participants
Start Date
July 12, 2012
Primary Completion Date
July 5, 2017
Study Completion Date
July 5, 2019
PLX3397
Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
Eribulin
Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
Duke University Cancer Center, Durham
Vanderbilt-Ingram Cancer Center, Nashville
University of California, San Francisco, San Francisco
Collaborators (1)
Susan G. Komen Breast Cancer Foundation
OTHER
Plexxikon
INDUSTRY
Hope Rugo, MD
OTHER